Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF

Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF

From CME by ReachMD

March 26, 2026 · 15 min

About this episode

Drs. Maria Pabon and Robert Mentz discuss the role of mineralocorticoid receptor antagonism in heart failure, focusing on patients at elevated biologic risk.

Faculty: Maria Pabon, MD Faculty: Robert J. Mentz, MD, FHFSA, FACC In this brief podcast, Drs. Maria Pabon and Robert Mentz explore the evolving role of mineralocorticoid receptor antagonism in heart failure, with emphasis on patients who appear clinically stable yet remain at elevated biologic risk. They contrast steroidal and nonsteroidal MRAs, highlighting differences in receptor selectivity, cardiac-renal distribution, and downstream anti-fibrotic and anti-inflammatory signaling. Faculty address the principle that symptom stability does not equate to disease stability, offering strategies to identify patients with HFpEF or HFmrEF who may benefit from a risk-based treatment approach.

People in this episode

Guests: Maria Pabon, MD, Robert J. Mentz, MD, FHFSA, FACC

Topics covered

  • mineralocorticoid receptor antagonism
  • heart failure
  • risk-based treatment
  • HFpEF
  • HFmrEF
  • anti-fibrotic signaling
  • anti-inflammatory signaling

Keywords

  • mineralocorticoid receptor antagonism
  • heart failure
  • HFpEF
  • HFmrEF
  • anti-fibrotic
  • anti-inflammatory
  • risk-based treatment

Mentioned in this episode

Organizations: ReachMD

More episodes of CME

Explore listener stats, chart rankings, contacts and more on the CME podcast page.